NYMOX PHARMACEUTICAL CORPORATION (NYMXF) Operating income 2015–2024
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) annual operating income history from SEC filings — each fiscal year as reported.
-$4.3MFY2024 · since FY2015: -$17.7M → -$4.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$4.3M | +48.7% |
| FY2023 | -$8.3M | -25.5% |
| FY2022 | -$6.7M | +46.8% |
| FY2021 | -$12.5M | -6.7% |
| FY2020 | -$11.7M | +12.0% |
| FY2019 | -$13.3M | -25.2% |
| FY2018 | -$10.6M | +19.6% |
| FY2017 | -$13.2M | -2.8% |
| FY2016 | -$12.9M | +27.1% |
| FY2015 | -$17.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NYMXF financial trends
NYMXF RevenueNYMXF Net incomeNYMXF Net marginNYMXF Gross profitNYMXF Gross marginNYMXF Operating marginNYMXF Operating cash flowNYMXF Free cash flowNYMXF Capital expendituresNYMXF Return on equityNYMXF Stock buybacksNYMXF Dividends paidNYMXF Total assetsNYMXF Total liabilitiesNYMXF Shareholders’ equityNYMXF overview →